
In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE
Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.
Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care.
Professor Matthias Augustin highlights the role of type 2 inflammation in chronic itch across distinct pruritic skin diseases and the cumulative burden of chronic itch and skin lesions in PN.

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the multidimensional and cumulative disease burden of AD and its associated comorbidities in children. Dr Boguniewicz also highlights the burden experienced by caregivers of children with AD

An interactive tool used to explore the global burden of atopic dermatitis in children and adolescents.
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
Join Prof. Alexandra Papadopoulou as she reviews the multifaceted burden of children with EoE.